Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported a director-level transaction on April 15, 2026, when director Saira Ramasastry sold 2,000 shares of the company's common stock for an aggregate of $193,800. The shares changed hands at $96.90 apiece, a price close to the then-current market quote of $95.86.
On the same date, Ramasastry also exercised stock options to acquire 2,000 shares of Mirum common stock at an exercise price of $23.51, for a total outlay of $47,020. Both the sale and the option exercise took place under a Rule 10b5-1 trading plan that Ramasastry previously adopted on September 18, 2025.
Mirum's shares have shown strong performance over the past year, delivering a roughly 145% return. At the same time, InvestingPro analysis cited in company reporting indicates that Mirum's shares may be trading above levels implied by its Fair Value estimate, suggesting valuation concerns at current prices.
Alongside the insider activity, several brokerages and research firms have reiterated or adjusted their views on Mirum and its prospects. Cantor Fitzgerald reiterated an Overweight rating and maintained a $140 price target, projecting 2026 revenue in the range of $630 million to $650 million and noting upside potential if Livmarli achieves success in the EXPAND study.
TD Cowen raised its price target to $125 from $117 while retaining a Buy rating, a move tied to preparation for data from a pivotal Phase IIb trial of volixibat in primary sclerosing cholangitis (PSC). Citizens continued to rate Mirum as Market Outperform with a $132 price target, calling 2026 a key year for HDV with multiple late-stage readouts and possible approvals anticipated.
Citizens also highlighted that enrollment in Mirum's Phase 3 EXPAND study is complete, and that the study's results—expected in the fourth quarter—could extend Livmarli's use beyond current indications by targeting a broader set of rare cholestatic pruritic disorders.
These analyst actions and the director's transaction occur as investors and market participants watch Mirum's pipeline and upcoming clinical data closely. The combination of insider activity, strong recent share performance, and concentrated analyst focus underscores investor interest in the company heading into several important clinical milestones in 2026.